- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | iSpecimen Inc.: iSpecimen Secures Suppliers for COVID-style hMPV Outbreak | 346 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus... ► Artikel lesen | |
| 16.01. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.01. | iSpecimen-Aktie erreicht 52-Wochen-Tief bei 2,6 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.01. | iSpecimen stock hits 52-week low at $2.6 amid market challenges | 2 | Investing.com | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| 30.12.24 | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.12.24 | iSpecimen stock hits 52-week low at $2.75 amid market challenges | 1 | Investing.com | ||
| 20.12.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | iSpecimen expands cancer biospecimen services for research | 3 | Investing.com | ||
| 20.12.24 | iSpecimen Inc.: iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens | 285 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025... ► Artikel lesen | |
| 13.12.24 | iSpecimen Up on Positive Results From NDQ | 2 | Baystreet.ca | ||
| 13.12.24 | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | 790 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| 13.12.24 | iSpecimen Inc.: iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers | 267 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12.24 | iSpecimen appoints Robert Lim as CEO | 1 | Seeking Alpha | ||
| 12.12.24 | iSpecimen Inc.: iSpecimen Appoints Robert Lim as CEO and Director | 435 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.24 | iSpecimen-Aktie erreicht 52-Wochen-Tief bei 3,4 US-Dollar | 1 | Investing.com Deutsch | ||
| 11.12.24 | iSpecimen stock hits 52-week low at $3.4 amid market challenges | 1 | Investing.com | ||
| 12.11.24 | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.11.24 | iSpecimen Inc.: iSpecimen Named Top Competitor in $4.4 Billion USD Market | 267 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 07.11.24 | iSpecimen Inc: iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually | 2 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 129,10 | -0,52 % | Inside the New Illumina MiSeq i100 Series: The Making of the Software | What's it like to build the software in a brand-new sequencer? Illumina's Aneesh Natarajan takes us on the journeyOriginally published on Illumina News Center NORTHAMPTON, MA / ACCESS Newswire / January... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,200 | -2,90 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results | -CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,870 | -5,64 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| EDITAS MEDICINE | 1,339 | +2,17 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 140,50 | -0,85 % | Neurocrine Biosciences Appoints SVP of Drug Development, Delivery and Device | ||
| BLUEBIRD BIO | 7,650 | +2,68 % | bluebird bio Announces 1-for-20 Reverse Stock Split | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 19,635 | -0,83 % | AKTIONÄR-Favorit Arrowhead Pharmaceuticals: Wichtiger Meilenstein | Gute Nachrichten von Arrowhead Pharmaceuticals am Freitagabend. Die US-Gesundheitsbehörde FDA hat den Antrag auf Marktzulassung des Unternehmens für Plozasiran zur Behandlung von Patienten mit einer... ► Artikel lesen | |
| GALAPAGOS NV | 22,680 | +0,35 % | Galapagos inks agreement with Catalent for experimental CAR-T therapy | ||
| CARDIFF ONCOLOGY | 3,280 | +0,77 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial | - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,980 | -4,71 % | Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgan's 'Neutral' Outlook | ||
| TWIST BIOSCIENCE | 50,16 | -2,60 % | Twist Bioscience Aktie: Kooperationen sorgen für Schub! | Die Twist Bioscience Corporation verzeichnete am 7. Dezember 2024 eine bemerkenswerte Entwicklung an der Börse. Der Aktienkurs stieg um 3,86 Prozent auf 52,70 USD, was die positive Monatsentwicklung... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 10,200 | -0,10 % | Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress | CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare... ► Artikel lesen | |
| XBIOTECH | 3,600 | +2,86 % | XFRA 4XB: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,839 | +1,21 % | Spero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes | Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice... ► Artikel lesen |
Das Unternehmen ISPECIMEN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,19 % bei einem Aktienkurs von 2,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.
